ABSI

Business Context and Reporting Period

Company: Absci Corp (ABSI)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2025
Business Overview: Absci is an emerging growth company advancing antibody therapeutics using generative AI design via its Integrated Drug Creation platform. The company operates through partnered drug creation programs and internally developed programs. As of April 30, 2025, the company had 127,559,352 shares of common stock outstanding.

Key Financial Metrics

Note: Cash, cash equivalents, and short-term investments for Q1 2024 calculated as $41,213 (Cash) + $15,947 (Restricted Cash) + $71,212 (Short-term investments) = $128,372. The table above reflects Q1 2025 liquidity of $134.0 million as stated in MD&A.

Material Changes vs. Prior Period

• Revenue Growth: Partner program revenue increased by $0.3 million (31%) to $1.2 million, driven by the timing of project-based milestones and ongoing program activity. Two partners accounted for approximately 95% of revenue in Q1 2025 (compared to 99% in Q1 2024).
• Expense Increases: Total operating expenses rose by $4.5 million (18%).
  • R&D Expenses: Increased by $4.1 million (34%) to $16.4 million, primarily due to the advancement of drug creation programs ($3.1 million) and increased personnel/stock-based compensation ($1.0 million).
  • SG&A Expenses: Increased by $0.7 million (8%) to $9.5 million, driven by higher stock-based compensation ($1.0 million) and administrative costs, partially offset by lower personnel costs.
• Net Loss: Net loss widened by $4.4 million to $26.3 million due to increased operating expenses outpacing revenue growth.
• Capital Raise: In January 2025, the company completed a $20.0 million PIPE transaction with Advanced Micro Devices (AMD) and raised an additional $21.7 million via its At-The-Market (ATM) program during the quarter.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes current cash, cash equivalents, and short-term investments ($134.0 million) are sufficient to meet operating and capital expenditure needs for at least the next 12 months.
• Pipeline Updates:
  • ABS-101: First-in-human Phase 1 clinical trial for Inflammatory Bowel Disease (IBD) initiated dosing in May 2025; interim readout expected in H2 2025.
  • ABS-201: Preclinical development ongoing for androgenic alopecia; potential regulatory filing targeted for H1 2026.
• Strategic Collaboration: A strategic collaboration with AMD aims to optimize AMD Instinct accelerators and ROCm software for Absci's AI drug creation models.
• Key Risks:
  • Capital Needs: The company expects to incur significant losses and will need to raise additional capital to fund operations and platform improvements.
  • Revenue Concentration: Heavy reliance on a limited number of partners for revenue.
  • Development Uncertainty: No product candidates have yet received regulatory approval; clinical trial results are inherently uncertain.
  • Regulatory Environment: Potential disruptions to FDA operations due to staffing cuts or government shutdowns could delay reviews.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $134.0 million cash position against the projected burn rate, given the $26.3 million quarterly net loss.
• Revenue Concentration: Assess the risk associated with two partners representing 95% of Q1 2025 revenue.
• AMD Collaboration Terms: Review the specific milestones and deliverables of the AMD strategic collaboration to understand future revenue or cost-sharing implications.
• Clinical Trial Progress: Monitor the initiation and interim data readout for the ABS-101 Phase 1 trial in H2 2025.
• Debt Obligations: Review the terms of the $3.2 million outstanding equipment financing and any associated covenants.